company background image
TCRX logo

TScan Therapeutics NasdaqGM:TCRX Stock Report

Last Price

US$1.59

Market Cap

US$87.7m

7D

-12.6%

1Y

-77.2%

Updated

18 Mar, 2025

Data

Company Financials +

TScan Therapeutics, Inc.

NasdaqGM:TCRX Stock Report

Market Cap: US$87.7m

TCRX Stock Overview

A clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. More details

TCRX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

TScan Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for TScan Therapeutics
Historical stock prices
Current Share PriceUS$1.59
52 Week HighUS$9.69
52 Week LowUS$1.51
Beta0.91
1 Month Change-22.44%
3 Month Change-45.17%
1 Year Change-77.19%
3 Year Change-52.68%
5 Year Changen/a
Change since IPO-84.86%

Recent News & Updates

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Mar 07

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

Feb 10

Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet?

Nov 06
Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet?

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Aug 26

Recent updates

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Mar 07

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

Feb 10

Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet?

Nov 06
Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet?

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Aug 26

Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

Mar 23
Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

Feb 17
Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Mar 11
TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

Aug 10

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

Jul 07

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

May 22
Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

Jan 17
Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Oct 18
We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Shareholder Returns

TCRXUS BiotechsUS Market
7D-12.6%0.6%1.7%
1Y-77.2%-3.0%10.0%

Return vs Industry: TCRX underperformed the US Biotechs industry which returned -3% over the past year.

Return vs Market: TCRX underperformed the US Market which returned 10% over the past year.

Price Volatility

Is TCRX's price volatile compared to industry and market?
TCRX volatility
TCRX Average Weekly Movement9.4%
Biotechs Industry Average Movement10.6%
Market Average Movement6.5%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market3.4%

Stable Share Price: TCRX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: TCRX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018195Gavin MacBeathwww.tscan.com

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also advanced TS-102 into IND-enabling activities.

TScan Therapeutics, Inc. Fundamentals Summary

How do TScan Therapeutics's earnings and revenue compare to its market cap?
TCRX fundamental statistics
Market capUS$87.72m
Earnings (TTM)-US$127.50m
Revenue (TTM)US$2.82m

32.0x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TCRX income statement (TTM)
RevenueUS$2.82m
Cost of RevenueUS$4.85m
Gross Profit-US$2.03m
Other ExpensesUS$125.47m
Earnings-US$127.50m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.25
Gross Margin-72.09%
Net Profit Margin-4,527.66%
Debt/Equity Ratio13.3%

How did TCRX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/18 22:55
End of Day Share Price 2025/03/18 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TScan Therapeutics, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Justin ZelinBTIG
Andrew FeinH.C. Wainwright & Co.